RPG Life Sciences shifts gears, bets on chronic drugs to expand sales, profits
The drugmaker wants the chronic segment to account for 50 percent of revenue. Currently, RPG Life Sciences’ business mix is heavily skewed towards acute drugs, with over two-thirds of sales coming from this segment